This stock is in 건강관리: revenue rank 219 of 290, share 0%.
219 / 2900%revenue share
HASS
A450330 · KOSDAQ₩3,945+4.09%
2026-08-03 closeHASS — what's the grade? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 295 건강관리 peers · not investment advice
Annual dividend
Split-adjusted annual DPS history and available grade axes
Consistency
D
Yield
C+
Paid 1 consecutive years · Raised 0 consecutive years · Yield 1.77% (based on 2025 payment of 70원)
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 7.76
Distress
Grey
Safe
- Altman Z''
- 7.76
- Beneish M-Score
- —
- Sloan accrual
- 1.17%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
2/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score2/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-03건강관리
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6하스0%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 14
- Median P/B
- 1.47
- Level
- 넓음
- n
- 269
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 7.7%
- Interest coverage
- 5x
- Return on equity (ROE)
- 3.9%
Operating margin −5pp
Severe margin pressureInterest coverageBase 5x adverse case 1.7x
Return on equity (ROE)Base 3.9% adverse case 0.4%
Revenue −15%
TolerableInterest coverageBase 5x adverse case 4.2x
Return on equity (ROE)Base 3.9% adverse case 1.8%
Interest rate +2pp
TolerableInterest coverageBase 5x adverse case 2.8x
Return on equity (ROE)Base 3.9% adverse case 1.8%
Interest coverage limit
Current margin 6.1ppInterest coverage limit at an operating margin of 1.5%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-19Suppliers disclosed by the company in its 2026-03-19 annual report.
Suppliers without disclosed amount
RMBUSDKOMIS
Financials at a glance
HASS's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 김용수60.72%2025-09-01 · 증감 +0.94%p
Connections
AI-extracted related companies · for reference
Customers
Henry ScheinPatterson Companies
Competitors
덴티움Price comovement r=0.38 (1 year)오스템임플란트디오Price comovement r=0.26 (1 year)메가젠임플란트Straumann GroupDentsply SironaEnvista Holdings
Same theme
Recent filings
HASS's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Signal history (last ~2 years)
Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.
Golden cross×1
26-05-14-22.1%
New MA alignment×2
26-05-06-32%26-04-20-10.7%
“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy